Asahi Kasei completes the acquisition of Aicuris to strengthen the infectious disease portfolio

JAPAN—Asahi Kasei, a diversified global company, has completed its acquisition of Aicuris Anti-infective Cures AG, a German biopharmaceutical firm specializing in severe infectious diseases.

The closing represents a significant milestone in Asahi Kasei’s strategy to build a comprehensive specialty pharmaceutical platform with a particular focus on infectious disease treatments.

Ken Shinomiya, Head of Asahi Kasei’s Healthcare Sector, outlined the strategic rationale behind the acquisition.

He explained that infectious diseases represent a core growth area characterized by sustained demand, significant unmet medical needs, and long-term revenue potential.

Aicuris brings a differentiated portfolio and advanced scientific capabilities that strengthen Asahi Kasei’s pipeline while creating immediate commercial opportunities.

By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.

Three key assets addressing market gaps

The acquisition brings three antiviral assets to Asahi Kasei’s portfolio, spanning both marketed and clinical-stage candidates. Prevymis®, an established treatment, generates a consistent royalty stream with key milestone payments.

Current projections estimate annual royalty revenue between USD100 million and USD200 million, contingent on sales performance.

Pritelivir represents the second asset and offers a near-term commercial opportunity.

The U.S. Food and Drug Administration granted Priority Review status to its New Drug Application, with a decision expected by the fourth quarter of 2026.

The drug targets approximately 15,000 immunocompromised patients in the United States and is expected to achieve meaningful market penetration in the second-line treatment setting, potentially reaching 70% adoption.

Analysts project peak revenues exceeding USD400 million in the mid-to-late 2030s.

AIC468 serves as the portfolio’s longer-term growth driver.

Currently in Phase I clinical trials, this candidate targets BK virus infection in kidney transplant and hematopoietic stem cell transplant recipients—an area of increasing clinical importance.

The potential market opportunity for AIC468 exceeds USD1 billion, reflecting substantial demand for effective treatments in this space.

Projected growth and integration plans

Collectively, these three assets create a balanced portfolio combining immediate royalty income, near-term commercial potential, and pipeline-driven growth.

Aicuris is projected to generate USD500 million in revenue by 2030, excluding AIC468 contributions.

Asahi Kasei will advance Aicuris’s pipeline through Veloxis Pharmaceuticals, Inc., its U.S. subsidiary and established leader in transplant medicine.

Stacy Wheeler, Veloxis’s chief executive officer, highlighted the strategic synergy, noting that Aicuris’s infectious disease expertise complements Veloxis’s transplant-focused research and commercial capabilities.

This integration addresses critical unmet medical needs among immunocompromised patient populations.

Asahi Kasei expects the acquisition to contribute positively to operating income after intangible asset amortization beginning in fiscal 2028.